Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuhan YZY Biopharma CoHKSE:02496 Pretax Margin % is -87.28% as of Dec. 2025. The stock has 8 warning signs investors should review. Among 942 Biotechnology companies, Wuhan YZY Biopharma Co ranks worse than 53.61% on this metric.
The historical rank and industry rank for Wuhan YZY Biopharma Co's Pretax Margin % or its related term are showing as below:
HKSE:02496'
s Pretax Margin % Range Over the Past 10 Years
Min: -126.73 Med: -108.63 Max: -90.53
Current: -126.55
HKSE:02496's Pretax Margin % is ranked worse than 53.61% of 942
companies
in the Biotechnology industry
Industry Median: -89.375
vs HKSE:02496: -126.55
Wuhan YZY Biopharma Co (HKSE:02496) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Wuhan YZY Biopharma Co Pretax Margin % Related Terms
Wuhan YZY Biopharma Co Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Wuhan YZY Biopharma Co's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02496 vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, Wuhan YZY Biopharma Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan YZY Biopharma Co Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Wuhan YZY Biopharma Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan YZY Biopharma Co (HKSE:02496) has a Pretax Margin % of -87.28% as of Dec. 2025. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Wuhan YZY Biopharma Co and its competitors. According to the industry distribution chart, Wuhan YZY Biopharma Co ranks #505 out of 942 companies in the Biotechnology industry, placing it in the top 53.6%.
Is Wuhan YZY Biopharma Co's Pretax Margin % too high?
Wuhan YZY Biopharma Co's current Pretax Margin % is -87.28%. Based on the distribution chart, Wuhan YZY Biopharma Co ranks #505 out of 942 companies in the Biotechnology industry, which is below the industry midpoint.
How does Wuhan YZY Biopharma Co's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Wuhan YZY Biopharma Co ranks #505 out of 942 companies for Pretax Margin %. This places Wuhan YZY Biopharma Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Wuhan YZY Biopharma Co and its competitors. Wuhan YZY Biopharma Co's current Pretax Margin % is -87.28%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan YZY Biopharma Co stock overvalued right now?
Wuhan YZY Biopharma Co (HKSE:02496) has a current Pretax Margin % of -87.28%. The current Pretax Margin % is -87.28%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Wuhan YZY Biopharma Co (HKSE:02496), the current Pretax Margin % is -87.28% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02496 has been successfully added to your 
